The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: Results from a phase II/III s tudy

Clinical Cancer Research

Volumn 20, Issue 12, 2014, Pages 3348-3357

  Heiss, Markus M ^a   Ströhlein, Michael A ^a   Bokemeyer, Carsten ^b   Arnold, Dirk ^b   Parsons, Simon L ^e   Seimetz, Diane ^c   Lindhofer, Horst ^d   Schulze, Elisabeth ^c   Hennig, Michael ^c  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Fresenius Biotech   (Germany)

^d TRION Pharma GmbH   (Germany)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATUMAXOMAB; BISPECIFIC ANTIBODY;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALIGNANT ASCITES; OVERALL SURVIVAL; PARACENTESIS; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELATIVE LYMPHOCYTE COUNT; SURVIVAL RATE; TREATMENT OUTCOME; ASCITES; BLOOD; CANCER STAGING; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, BISPECIFIC; ASCITES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAPERITONEAL; LYMPHOCYTE COUNT; NEOPLASM STAGING; PARACENTESIS; PROGNOSIS; SURVIVAL RATE;

EID: 84902660533     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2351     Document Type: Article

References (33)

1. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010;36:458-67.
2. Lindhofer H, Hess J, Ruf P. Trifunctional Triomab® antibodies for cancer therapy. In:Kontermann RE, editor. Bispecific antibodies. Berlin, Germany: Springer; 2011. p. 289-312.
3. Ruf P, Gires O, Jager M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007;97:315-21. (Pubitemid 47196752)
4. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-34.
5. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6. (Pubitemid 30411727)
6. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 2001;49:911-7. (Pubitemid 32565984)
7. Ott MG, Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 2012;130:2195-203.
8. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-21.
9. Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trail. Onkologie 2011;34:101-10.
10. Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, et al. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011;123:27-32.
11. Ströhlein MA, Lefering R, Bulian DR, Heiss MM. Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy. Med Hypotheses 2014;82:295-9.
12. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011;17:3064-76.
13. Characiejus D, Hodzic J, Jacobs JJ. "First do no harm" and the importance of prediction in oncology. EPMA J 2010;1:369-75.
14. Characiejus D, Jacobs JJ, Pasukoniene V, Kazlauskaite N, Danileviciute V, Mauricas M, et al. Prediction of response in cancer immunotherapy. Anticancer Res 2011;31:639-47.
15. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011;60:433-42.
16. Khleif SN, Doroshow JH, Hait WN. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010;16:3299-318.
17. Ströhlein M, Heiss M. Catumaxomab treatment of peritoneal carcinomatosis from EpCAM-positive cancer: identification of biomarkers with relevance for improved efficacy and survival. J Clin Oncol 2009;29:2011 (suppl; abstr e13003).
18. European Medicines Agency. ICH Topic E9: statistical principles for clinical trials. Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500002928.pdf.
19. Lange S. The all randomized/full analysis set (ICHE9) - may patients be excluded from the analysis? Drug Info J 2001;35:881-91.
20. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl JMed 2007;357:2189-94.
21. Mandrekar J, Mandrekar S, Cha S. Cutpoint determination methods in survival analysis using SAS. SUGI 2003;28:261-82.
22. Jager M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res 2012;72:24-32.
23. Goere D, Flament C, Rusakiewicz S, Poirier-Colame V, Kepp O, Martins I, et al. Potent immunomodulatory effects of the trifunctional antibody catumaxomab. Cancer Res 2013;73:4663-73.
24. Strohlein MA, Siegel R, Jager M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009;28:18.
25. Aliustaoglu M, Bilici A, Ustaalioglu BB, Konya V, Gucun M, Seker M, et al. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 2010;27:1060-5.
26. Milasiene V, Stratilatovas E, Norkiene V. The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients. Medicina 2007;43:548-54.
27. Wada J, Yamasaki A, Nagai S, Yanai K, Fuchino K, Kameda C, et al. Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients. Anticancer Res 2008;28:2401-8.
28. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58:15-23.
29. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009;16:614-22.
30. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13:170-6.
31. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6:283-7. (Pubitemid 38987537)
32. el-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 1987;139:2406-13. (Pubitemid 17152141)
33. An X, Ding PR, Wang FH, Jiang WQ, Li YH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol 2011;32:317-24.